The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).

Karthik  Ramakrishnan

Stock and Other Ownership Interests  - Merck Sharp & Dohme; Novartis

Disha  Jain

No Relationships to Disclose

Jyotika  Gandhi

No Relationships to Disclose

Diana Romana  Chirovsky

Employment - Merck

Stock and Other Ownership Interests  - Merck

Rebekah  Borse

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck Sharp & Dohme